Department of Dermatology, Naval Medical Center San Diego, California.
Cutis. 2021 Apr;107(4):216-220. doi: 10.12788/cutis.0231.
Apremilast is a small-molecule biologic approved by the US Food and Drug Administration (FDA) for use in plaque psoriasis, psoriatic arthritis, and Behçet disease. Although apremilast is seemingly a less favorable choice for treating psoriasis in the era of injectable biologics, the drug is an important option for patients in the military. In this article, we review on-label indications and off-label uses for apremilast; highlight the importance of apremilast for managing psoriasis in the military population; and propose other patient populations in whom the use of apremilast is favorable. We also present a case report that highlights and embodies the benefit of apremilast for military service members.
阿普米司特是一种小分子生物制剂，已获得美国食品和药物管理局（FDA）批准用于治疗斑块状银屑病、银屑病关节炎和贝赫切特病。尽管在生物制剂注射的时代，阿普米司特治疗银屑病似乎不是一个理想的选择，但该药对军队患者来说是一个重要的选择。在本文中，我们回顾了阿普米司特的标签内适应证和标签外用途；强调了阿普米司特对管理军队人群中银屑病的重要性；并提出了其他适合使用阿普米司特的患者人群。我们还报告了一个病例，突出并体现了阿普米司特对军队服务人员的益处。
